Naslov
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches

Autori
Saraon, Punit ; Pathmanathan, Shivanthy ; Snider, Jamie ; Lyakisheva, Anna ; Wong, Victoria ; Štagljar, Igor

Izvornik
Oncogene (0950-9232) 40 (2021), 24; 4079-4093

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
TARGETED PROTEIN-DEGRADATION ; ANTITUMOR-ACTIVITY ; EGFR MUTANTS ; ACTIVATION ; GROWTH ; MET ; RESISTANCE ; INHIBITION ; DRIVEN ; CELLS

Sažetak
Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK dysregulation have been identified, resulting in multiple cancer types displaying 'oncogenic addiction' to RTKs. As a result, RTKs have represented a major class for targeted therapeutics over the past two decades, with numerous small molecule-based tyrosine kinase inhibitor (TKI) therapeutics having been developed and clinically approved for several cancers. However, many of the current RTK inhibitor treatments eventually result in the rapid development of acquired resistance and subsequent tumor relapse. Recent technological advances and tools are being generated for the identification of novel RTK small molecule therapeutics. These newer technologies will be important for the identification of diverse types of RTK inhibitors, targeting both the receptors themselves as well as key cellular factors that play important roles in the RTK signaling cascade.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA